<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01921894</url>
  </required_header>
  <id_info>
    <org_study_id>SAVED-P</org_study_id>
    <nct_id>NCT01921894</nct_id>
  </id_info>
  <brief_title>Vitamin D and Severe Asthma Exacerbations</brief_title>
  <acronym>SAVED-P</acronym>
  <official_title>A Phase I Trial for Children With Vitamin D Insufficiency and High Risk of Severe Asthma Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study of vitamin D is designed to assess both the safety and efficacy of potential doses
      (2,000 IU/day and 4,000 IU/day) in raising a vitamin D level to a normal range in a short
      period of time (e.g. 4 weeks or less) compared to 200 IU/day.

      In children with vitamin D insufficiency or deficiency who are at risk for severe asthma
      exacerbations, we hypothesize that both vitamin D supplementation with 4,000 IU/day and 2,000
      IU/day will safely achieve normal vitamin D levels, but that the higher dose (4,000 IU/day)
      will result in a larger proportion of subjects achieving this level at 4 and 8 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is a major public health problem in the United States and worldwide. Severe disease
      exacerbations account for the majority of costs attributable to asthma in the United States.
      Vitamin D is an essential nutrient with significant immuno-modulatory effects. The
      observation that vitamin D insufficiency and asthma share risk factors such as urban
      residence, obesity, and African American ethnicity has generated significant interest in
      exploring a link between these two conditions.

      This is an 8-week randomized, double-masked, controlled trial of vitamin D3 (2,000 IU/day and
      4,000 IU/day) to achieve vitamin D sufficiency (a serum 25(OH)D ≥30 ng/ml in 60 school-aged
      children (ages 6 to 14 years) who have vitamin D insufficiency (a serum 25(OH)D &lt;30 ng/ml)
      and are at risk for severe asthma exacerbations, but whose asthma that is well-controlled on
      medium-dose inhaled corticosteroid (ICS) at the end of a 4-week run-in period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Sufficient Vitamin D Levels (≥30 ng/ml) After 8 Weeks of Supplementation</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary outcome of the proposed trial will be a sufficient (≥30 ng/ml) vitamin D level after 8 weeks of supplementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vitamin D Sufficiency (Vitamin D ≥30 ng/ml) After 4 Weeks of Supplementation</measure>
    <time_frame>4 weeks</time_frame>
    <description>The outcome is defined as the number of participants with a sufficient (≥30 ng/ml) vitamin D level after 8 weeks of supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vitamin D Toxicity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Participants with vitamin D toxicity, hypercalcemia (&gt;10.8mg/dl) and/or an elevated urine Ca/Cr ratio (&gt;0.37)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Elevated Urinary Calcium/Creatinine Ratio</measure>
    <time_frame>4 and/or 8 weeks</time_frame>
    <description>Elevated urinary calcium/creatinine ratio defined as UCa/UCr &gt; 0.37 after either 4 weeks or 8 weeks of supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With FEV1 &lt; 80% of Predicted</measure>
    <time_frame>8 weeks</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1) as percent predicted (with reference values used according to the child's age, gender and ethnicity).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Cholecalciferol 4000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholecalciferol 4000 IU oral chewable tablet once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalciferol 2000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholecalciferol 2000 IU oral chewable tablet once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalciferol 200 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cholecalciferol 200 IU oral chewable tablet once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.</description>
    <arm_group_label>Cholecalciferol 4000 IU</arm_group_label>
    <arm_group_label>Cholecalciferol 2000 IU</arm_group_label>
    <arm_group_label>Cholecalciferol 200 IU</arm_group_label>
    <other_name>vitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 6 years of age and younger than 15 years of age

          -  Have physician-diagnosed asthma

          -  Taking a medium dose of ICS (e.g. fluticasone 220mcg BID) for daily asthma control for
             at least 6 months in the prior year.

          -  Have had a severe asthma exacerbation in the previous year, defined as an Emergency
             Department (ED) visit, hospitalization, or unscheduled clinic visit for asthma
             resulting in intramuscular, intravenous, or oral steroids.

          -  Have bronchodilator responsiveness (BDR, an increase in FEV1 ≥12% from baseline after
             administration of inhaled albuterol) or (if no BDR) increased airway responsiveness to
             methacholine challenge

          -  Have vitamin D insufficiency (a serum vitamin D (25(OH)D) level &lt;30 ng/ml)

          -  Have his/her parents give voluntary written consent to participate in the study

        Exclusion Criteria:

          -  Chronic respiratory disorder other than asthma (e.g., bronchiectasis).

          -  Severe asthma, as evidenced by any of the following: a) chronic need for medication
             other than single controller therapy and inhaled β2-agonist, b) intubation for asthma
             at any time, and c) ≥2 hospitalizations or ≥6 severe asthma exacerbations in the
             previous year

          -  History of cigarette smoking in the prior year or former smoking if ≥5 pack-years

          -  Hepatic or renal disease, metabolic rickets, malabsorptive disorders, or other chronic
             diseases that would affect vitamin D metabolism

          -  Immune deficiency, cleft palate or Down's syndrome, which might increase the child's
             likelihood of respiratory infections

          -  Treatment with anticonvulsants or pharmacological doses of vitamin D (≥1,000 IU/day of
             vitamin D2 or D3)

          -  Chronic oral corticosteroid therapy

          -  Inability to perform acceptable spirometry

          -  Use of investigational therapies or participation in clinical trials 30 days before or
             during the duration of the study

          -  Serum calcium &gt;10.8 mg/dl

          -  Serum 25(OH) D &lt;10 ng/ml (severe vitamin D deficiency)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan C Celedon, M.D., Dr.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2013</study_first_submitted>
  <study_first_submitted_qc>August 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2013</study_first_posted>
  <results_first_submitted>February 15, 2016</results_first_submitted>
  <results_first_submitted_qc>February 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2017</results_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Juan Celedon, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from: 1) the Emergency Department of Children’s Hospital of Pittsburgh (CHP), 2) the Pulmonary Medicine and Allergy clinics of CHP, 3) the General Pediatric Clinics of CHP, and 4) participants in a prior study of the Pediatric Environmental Medicine Center of CHP (who had consented to be contacted about studies of asthma).</recruitment_details>
      <pre_assignment_details>We recruited 48 children who met initial inclusion/exclusion criteria. Of these 48 children, 20 were excluded because of a 25(OH)D ≥30 ng/ml (n=13) or lack of bronchodilator response or airway responsiveness (n=7) at visit 1. Of the 28 remaining children, 4 were excluded because of non-adherence or poor asthma control during the run-in period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cholecalciferol 4000 IU</title>
          <description>Cholecalciferol 4000 IU oral chewable tablet once daily for 8 weeks
Cholecalciferol: vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.</description>
        </group>
        <group group_id="P2">
          <title>Cholecalciferol 2000 IU</title>
          <description>Cholecalciferol 2000 IU oral chewable tablet once daily for 8 weeks
Cholecalciferol: vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.</description>
        </group>
        <group group_id="P3">
          <title>Cholecalciferol 200 IU</title>
          <description>Cholecalciferol 200 IU oral chewable tablet once daily for 8 weeks
Cholecalciferol: vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cholecalciferol 4000 IU</title>
          <description>Cholecalciferol 4000 IU oral chewable tablet once daily for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Cholecalciferol 2000 IU</title>
          <description>Cholecalciferol 2000 IU oral chewable tablet once daily for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Cholecalciferol 200 IU</title>
          <description>Cholecalciferol 200 IU oral chewable tablet once daily for 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-Hispanic white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic/Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Sufficient Vitamin D Levels (≥30 ng/ml) After 8 Weeks of Supplementation</title>
        <description>The primary outcome of the proposed trial will be a sufficient (≥30 ng/ml) vitamin D level after 8 weeks of supplementation</description>
        <time_frame>8 weeks</time_frame>
        <population>In this pilot study, we wanted to report and compare the proportion of subjects who achieved vitamin D sufficiency after 8 weeks of treatment with one of three vitamin D doses.</population>
        <group_list>
          <group group_id="O1">
            <title>Cholecalciferol 4000 IU</title>
            <description>All participants randomized to 4000 IU per day were analyzed. Outcome was defined as having vitamin D ≥30 ng/ml after 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol 2000 IU</title>
            <description>All participants randomized to 2000 IU per day were analyzed. Outcome was defined as having vitamin D ≥30 ng/ml after 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cholecalciferol 200 IU</title>
            <description>All participants randomized to 200 IU per day were analyzed. Outcome was defined as having vitamin D ≥30 ng/ml after 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sufficient Vitamin D Levels (≥30 ng/ml) After 8 Weeks of Supplementation</title>
          <description>The primary outcome of the proposed trial will be a sufficient (≥30 ng/ml) vitamin D level after 8 weeks of supplementation</description>
          <population>In this pilot study, we wanted to report and compare the proportion of subjects who achieved vitamin D sufficiency after 8 weeks of treatment with one of three vitamin D doses.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Vitamin D Toxicity</title>
        <description>Participants with vitamin D toxicity, hypercalcemia (&gt;10.8mg/dl) and/or an elevated urine Ca/Cr ratio (&gt;0.37)</description>
        <time_frame>8 weeks</time_frame>
        <population>We wanted to report and compare the proportion of subjects who had vitamin D toxicity, hypercalcemia or an elevated UCa/UCr ratio across the three treatment arms</population>
        <group_list>
          <group group_id="O1">
            <title>Cholecalciferol 4000 IU</title>
            <description>All participants randomized to 4000 IU per day were analyzed. Outcome was defined as having vitamin D toxicity, hypercalcemia (&gt;10.8 mg/dl) or elevated uCa/uCr (&gt;0.37).</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol 2000 IU</title>
            <description>All participants randomized to 2000 IU per day were analyzed. Outcome was defined as having vitamin D toxicity, hypercalcemia (&gt;10.8 mg/dl) or elevated uCa/uCr (&gt;0.37).</description>
          </group>
          <group group_id="O3">
            <title>Cholecalciferol 200 IU</title>
            <description>All participants randomized to 200 IU per day were analyzed. Outcome was defined as having vitamin D toxicity, hypercalcemia (&gt;10.8 mg/dl) or elevated uCa/uCr (&gt;0.37).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vitamin D Toxicity</title>
          <description>Participants with vitamin D toxicity, hypercalcemia (&gt;10.8mg/dl) and/or an elevated urine Ca/Cr ratio (&gt;0.37)</description>
          <population>We wanted to report and compare the proportion of subjects who had vitamin D toxicity, hypercalcemia or an elevated UCa/UCr ratio across the three treatment arms</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Elevated Urinary Calcium/Creatinine Ratio</title>
        <description>Elevated urinary calcium/creatinine ratio defined as UCa/UCr &gt; 0.37 after either 4 weeks or 8 weeks of supplementation</description>
        <time_frame>4 and/or 8 weeks</time_frame>
        <population>We wanted to compare the proportion of subjects who had an elevated UCa/UCr ratio across the three groups in this pilot Phase I Study</population>
        <group_list>
          <group group_id="O1">
            <title>Cholecalciferol 4000 IU</title>
            <description>All participants randomized to 4000 IU per day were analyzed. Outcome was defined as having urinary calcium/creatinine ratio &gt; 0.37</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol 2000 IU</title>
            <description>All participants randomized to 2000 IU per day were analyzed. Outcome was defined as having urinary calcium/creatinine ratio &gt; 0.37</description>
          </group>
          <group group_id="O3">
            <title>Cholecalciferol 200 IU</title>
            <description>All participants randomized to 2000 IU per day were analyzed. Outcome was defined as having urinary calcium/creatinine ratio &gt; 0.37</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Elevated Urinary Calcium/Creatinine Ratio</title>
          <description>Elevated urinary calcium/creatinine ratio defined as UCa/UCr &gt; 0.37 after either 4 weeks or 8 weeks of supplementation</description>
          <population>We wanted to compare the proportion of subjects who had an elevated UCa/UCr ratio across the three groups in this pilot Phase I Study</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With FEV1 &lt; 80% of Predicted</title>
        <description>Forced expiratory volume in 1 second (FEV1) as percent predicted (with reference values used according to the child's age, gender and ethnicity).</description>
        <time_frame>8 weeks</time_frame>
        <population>We wanted to compare the proportion of subjects whose FEV1 % predicted fell below 80% predicted across the three arms in this pilot Phase I study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cholecalciferol 4000 IU</title>
            <description>All participants randomized to 4000 IU per day were analyzed. Outcome was defined having FEV1 &lt; 80% of predicted</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol 2000 IU</title>
            <description>All participants randomized to 2000 IU per day were analyzed. Outcome was defined having FEV1 &lt; 80% of predicted</description>
          </group>
          <group group_id="O3">
            <title>Cholecalciferol 200 IU</title>
            <description>All participants randomized to 200 IU per day were analyzed. Outcome was defined having FEV1 &lt; 80% of predicted</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With FEV1 &lt; 80% of Predicted</title>
          <description>Forced expiratory volume in 1 second (FEV1) as percent predicted (with reference values used according to the child's age, gender and ethnicity).</description>
          <population>We wanted to compare the proportion of subjects whose FEV1 % predicted fell below 80% predicted across the three arms in this pilot Phase I study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vitamin D Sufficiency (Vitamin D ≥30 ng/ml) After 4 Weeks of Supplementation</title>
        <description>The outcome is defined as the number of participants with a sufficient (≥30 ng/ml) vitamin D level after 8 weeks of supplementation</description>
        <time_frame>4 weeks</time_frame>
        <population>The characteristics of the study population are the same as described for the other primary outcome (vitamin D sufficiency at 8 weeks)</population>
        <group_list>
          <group group_id="O1">
            <title>Cholecalciferol 4000 IU</title>
            <description>All participants randomized to 4000 IU per day were analyzed. Outcome was defined as having vitamin D ≥30 ng/ml after 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol 2000 IU</title>
            <description>All participants randomized to 2000 IU per day were analyzed. Outcome was defined as having vitamin D ≥30 ng/ml after 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cholecalciferol 200 IU</title>
            <description>All participants randomized to 2000 IU per day were analyzed. Outcome was defined as having vitamin D ≥30 ng/ml after 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vitamin D Sufficiency (Vitamin D ≥30 ng/ml) After 4 Weeks of Supplementation</title>
          <description>The outcome is defined as the number of participants with a sufficient (≥30 ng/ml) vitamin D level after 8 weeks of supplementation</description>
          <population>The characteristics of the study population are the same as described for the other primary outcome (vitamin D sufficiency at 8 weeks)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cholecalciferol 4000 IU</title>
          <description>All participants randomized to 4000 IU per day were analyzed. Outcome includes any report of adverse events.</description>
        </group>
        <group group_id="E2">
          <title>Cholecalciferol 2000 IU</title>
          <description>All participants randomized to 2000 IU per day were analyzed. Outcome includes any report of adverse events.</description>
        </group>
        <group group_id="E3">
          <title>Cholecalciferol 200 IU</title>
          <description>All participants randomized to 200 IU per day were analyzed. Outcome includes any report of adverse events.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Juan C. Celedon, Niels K. Jerne Professor of Pediatrics</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-692-8429</phone>
      <email>juan.celedon@chp.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

